Document Classification

Section Type: RESULTS

Text: For first-line therapy, patients in the EDP-mitotane group had a significantly higher response rate than those in the streptozocin-mitotane group (23. 2 % vs. 9. 2 %, P < 0. 001) and longer median progression-free survival (5. 0 months vs. 2. 1 months ; hazard ratio, 0. 55 ; 95 % confidence interval [CI], 0. 43 to 0. 69 ; P < 0. 001) ; there was no significant between-group difference in overall survival (14. 8 months and 12. 0 months, respectively ; hazard ratio, 0. 79 ; 95 % CI, 0. 61 to 1. 02 ; P = 0. 07).